INTRODUCTION
Corticosteroids or corticoids refers to natural gluco and mineralocorticoids and their synthetic analogues. Natural : Adrenal cortex produces mineralocorticoids i.e. aldosterone & glucocorticoids i.e. hydrocortisone (cortisol) Synthetic steroids : include Prednisolone, Methylprednisolone, dexamethasone, Betamethasone, Deflazacort and Triamcinolone
2
Pregnenolone
Progesterone
Oestrone
11-Desoxycorticosterone
Basal secretions
Group Glucocorticoids Hormone Cortisol Corticosterone Daily secretions 5 30 mg 2 5 mg
Mineralocorticoids Aldosterone 5 150 mcg 11- deoxycorticosterone Trace Sex Hormones Androgen Progestogen Oestrogen DHEA Progesterone Oestradiol 15 30 mg 0.4 0.8 mg
Trace
Circadian Rhythm
Mechanism of action
Corticosteroids act via receptors which are present in almost all the cells of the body. Corticosteroids diffuse in to target cells where they combine with steroid receptors in the cytoplasm. The activated drug receptor complex enters nucleus and binds to an element on RNA molecule mRNA protein synthesis steroid response.
8
Physiological effects
Alteration in carbohydrate, protein and fat metabolism. Maintenance of fluid and electrolyte balance. Normal functioning of CVS, immune system, kidney, skeletal muscles and nervous system. Provides resistance to stress and noxious stimuli and environment changes. Permits and facilitates action of other hormones permissive action.
9
Anti-inflammatory effect
Recruitment of WBC & monocyte- macrophage into affected area & elaboration of chemotactic substances. Lipocortin ELAM1 & ICAM-1 in endothelial cells TNF from phagocytic cells IL1 from monocyte-macrophage Formation of Plasminogen Activator Action of MIF & fibroblastic activity
10
Expression of cyclooxygenase II
11
12
13
Pharmacokinetics
Absorption: all are rapidly & completely absorbed.
oral bioavailability of synthetic steroids is high. (Except DOCA)
Transport:
Transcortin 75% Albumin 5% Free form 20%
Metabolism:
by liver enzymes, conjugation & excretion by urine Hydrocortisone undergoes high 1st pass metabolism. Synthetic steroids undergo reduction in liver to active metabolites. partly excreted as 17-ketosteroids. t1/2 of cortisol 1.5 hours
14
PREPARATIONS
15
CLASSIFICATION
By chemical structure : 4 gps.
Group A Group B Group C Group D
ROUTES OF ADMINISTRATION
Oral forms Prednisone Prednisolone / Methylprednisolone Betamethasone /dexamethasone Fludrocortisone Hydrocortisone /cortisone Triamcinolone Deflezacort Injectable forms Hydrocortisone Betamethasone dexamethasone Prednisolone Methylprednisolone Triamcinolone
Inhaled steroids Flunisolide Fluticasone propionate Triamcinolone acetonide Beclomethasone dipropionate Budesonide Mometasone Ciceclosonide
17
Short Acting Preparations (t1/2 < 12 h) (8-12 hrs) Drug Cortisol (8-12 hrs) Antiinflam. 1 Salt retaining 1 Topical 1
Preapartions & dose 5 mg tablet 100 mg/vial (i.m., i.v) Topical; enema 5 mg tablet 25 mg/vial (i.m)
Cortisone
0.8
0.8
4 5
0.8 0.3
0 4
5, 10 mg tablet 20 mg/vial (i.m, intrarti) 0.5, 1.0 gm inj. for i.m. or slow i.v. 4 mg Tab., 10, 40 mg/ml for 18 i.m. &intrarticular inj.
Methyl prednisolone
Triamcinolone
5 5
0 0
5 5
Drug
Topical
Long Acting Preparations (t1/2 > 36 h) (36-54 hrs) Dexamethasone 25 0 10 0.5 mg tab. 4mg/ml inj (i.m., i.v.) 0.5, 1 mg tab. 4mg/ml inj (i.m., i.v.) 2- 20 mg/day (oral)
Betamethasone
25
10
Paramethasone
10
MINERALOCORTICOIDS
Fludrocortisone
10
150
10
DOCA Aldosterone
0 0.3
100 3000
0 -
Inhaled Steroids
Beclomethasone dipropionate Fluticasone propionate Budesonide 50,100,200 mcg/md MDI 100, 200, 400 mcg Rota caps 50,125 , 250 mcg/md MDI 100, 250, 500 mcg Rotacaps 0.5, 2.0 mg/ml respules 100,200 mcg/md MDI 100, 200, 400 mcg Rotacaps 0.5, 1.0 mg/ml respules
21
Inhaled steroids
Budesonide :
Low dose
Adult: 200-400 mcg Child: 100-200mcg
Medium dose
Adult: 400-800 mcg Child : >200-400mcg
High dose
Adult: >800-1600 mcg Child: >400mcg
Fluticasone :
Low dose
Adult: 100-250mcg) Child: 100-200mcg
Medium dose
Adult: >250-500 mcg Child: >200-500 mcg
High dose
Adult: >500-1000mcg Child: >500 mcg
22
Inhaled steroids
Beclomethasone Dipropionate
Low dose
Adult: 200-500 mcg/day Child: 100-200 mcg/day
Medium dose
Adult: >500-1000 mcg/day Child: >200-400 mcg/day
High dose
Adult: >1000-2000 mcg/day Child: >400 mcg/day
Triamcinolone
Dose per puff: 100 mcg/puff Low dose
Adult: 400-1000 mcg/day Child: 400-800 mcg/day
Medium dose
Adult: >1000-2000 mcg/day Child: >800-1200 mcg/day
High dose
Adult: >2000 mcg/day Child: >1200 mcg/day
23
Inhaled steroids
Mometasone
Low dose
Adult: 200-400 mcg/day Child: 100-200 mcg/day
Medium dose
Adult: >400-800 mcg/day Child: >200-400 mcg/day
High dose
Adult: >800-1200 mcg/day Child: >400 mcg/day
Cicelosonide
Low dose
Adult: 80-160 mcg/day Child: 80-160 mcg/day
Medium dose
Adult: >160-320 mcg/day Child: >160-320 mcg/day
High dose
Adult: >320-1280 mcg/day Child: >320 mcg/day
24
Clinical application
Therapeutic Replacement therapy Non endocrine uses Diagnostic
Physiological doses are used for replacement therapy in endocrine diseases. Supra physiological doses are used for their anti inflammatory effects in arthritis, asthma, inflammatory bowel diseases etc. In organ transplant and autoimmune disorders, steroids are used for their immunosuppressive effect.
25
Diagnostic Uses
Cushings syndrome: ACTH dependent (pituitary tumor, ectopic
ACTH secreting tumors)
Therapeutic principles
Endocrine Disorders
Acute adrenal insufficiency Primary adrenocortical insufficiency Ad. Insufficiency second. to Ant. Pituitary Congenital adrenal hyperplasia
Isotonic saline Glucose Hydrocortisone inj. i.v. Gradullay substitue with i.m or oral Addisons disease Oral cortisol (20 +10 mg) Fludrocortisone (0.1 or 0.2 mg daily, p.o.)
28
RESPIRATORY DISEASES
29
Bronchial Asthma
Indications : Status asthmatic
methyl prednisolone 120 mg / day iv in divided doses for 24 to 72 h, oral prednisone at 60 mg daily, (when the FEV1 reaches a threshold of 50 percent of predicted normal) 2 7 days ; gradual tapering of the dose over 1 to 3wk.
Systemic steroids not preffered in chronic stable asthma. Inhaled steroids preferably in combination with LABA are prescribed in moderate to severe asthma.
30
COPD
Indications : Stage 3 & 4 ; FEV1<50% ; frequent exacerbations- inhaled corticosteroids are given in combination with LABA. In case of acute exacerbation, a short course of medium dose i.e. 40 mg/day is given for short course, 7-14 days. Long course therapy with corticosteroids is avoided as it leads to steroid induced myopathy which further worsens the respiratory functioning.
31
Tuberculosis
Indications : TB of adrenal gland or associated addisons disease ; absolute indication. Seriously ill patient/ miliary TB/ severe pulmonary TB (2030mg/day) Disseminated TB with hypoxemia; higher dose given (6080mg/day) AIDS patient with severe manifestations Hypersensitivity reactions to drugs Tubercular meningitis (60-80mg/day iv in divided doses; converted to oral and tapered gradually over 8-12 wks) Genitourinary TB / Tubercular pericarditis / pleural effusion/tubercular lymphadenitis. Endobronchial tuberculosis esp. children Local steroid therapy for BCG related keloid reaction. C/I Intestinal TB ( coz of risk of silent perforation) Dose usually 20mg/day ; 40 mg if rifampicin is used ; higher in severe conditions. 32 Caution never use without adequate chemotherapy cover.
ARDS
Steroids may have a role in chronic ARDS in patients, without infection, with high O2 requirements days to weeks into the disease process. The patient must have no demonstrable infection Steroids should not be started less than 7 days, or more than 28 days, from admission. The patient should not have a history of gastric ulceration of active gastrointestinal bleeding. The patient should have evidence of ALI and require an FiO2 >/= 50% The steroid regimen: Loading dose 2mg/kg Then 2mg/kg/day from day 1 to 14 Then 1mg/kg/day from day 15 to 21 Then 0.5mg/kg/day from day 22 to 28 Then 0.25mg/kg/day on days 29 and 30 Finally 0.125mg/kg on days 31 and 32.
33
Others
IPF & other ILDs
1st line therapy as per ATS guidelines is combination of corticosteroids and immunosuppressive agents Dose - 0.5 mg/kg/day orally 4wks ; 0.25mg/kg/day orally 8wks ; 0.25mg/kg every other day.
Hypersensitivity pneumonitis
indicated in severely symptomatic patient. Dose - 40-60 mg/day 2wks ; tapered over 2-4wks.
34
Contd
Sarcoidosis
Mainstay of treatment Dose - 20-40mg/day 2 wks ; tapered by 5mg every 2 wks ; maintenance dose of 10-15mg/day 8-12mths.
ABPA
Mainstay of treatment Dose- 0.5-1.0mg/kg/day orally 1-2 wks; 0.5mg/kg alternate day 6-12wks / maintenance dose of 7.5 mg/day.
35
Contd
Antenatal
used frequently in premature labour. Decrease incidence of RDS, IVH and death. Dose Betamethasone 12 mg im every 24 hrs 2doses or Dexamethasone 6 mg im every 12 hrs 4 doses administered to women with premature labour between 27 34 wks.
Contd
Bronchiectasis
controversial may reduce sputum volume & purulence and decrease exacerbations.
Cystic fibrosis
to decrease airway inflammation.
Contd
Lung transplantation
pre-operatively Methyl prednisolone 500mg iv; postop methyl prednisolone 125 mg iv 8 hrly prednisolone 20mg/day for 7-14 days.
Pulmonary vasculitidis
Wagener's granulomatosis, churg strauss syndrome, poly arteritis nodosa.
Non-endocrine diseases
1. Arthritis
Prednisolone 5 or 7.5 mg (5-10 mg/day) Intra-articular injection (prednisolone 10-40mg; triamcinolone 5-20 mg) 2. Rheumatic carditis Severely ill pts. Prednisolone 40mg in divided doses or 1-2 mg/kg 3 days; followed by reduction of 5 mg / wk. 3. Allergic diseases Anaphylactic shock, blood transfusion reaction, hay fever Prednisolone (short course)
39
Non-endocrine diseases
4. Renal diseases (Nephrotic syndrome)
Prednisolone 60 mg (2mg/kg) in divided doses for 3 4 weeks followed by gradual tapering over 6 8 wks. If remission occurs continue for 1 year Do not modify the course of disease; Some may benefit 5. Collagen diseases DLE, pemphigus vulgaris, polyarteritis nodosa Defect in connective tissue proteins in joints, various organs and deeper layer of skin Prednisolone 1mg/Kg start; gradually reduce the dose
40
Non-endocrine diseases
6. Ocular diseases
Outer eye & anterior segment: local application Posterior segment: systemic use Caution: bacterial, viral & fungal conjunctivitis 7. Dermatological conditions Pemphigus: Life saving therapy is steroids Eczema, dermatitis & psoriasis: respond well
41
Non-endocrine diseases
8. Diseases of intestinal Tract Ulcerative colitis: cortisol retention enema 9. Cerebral oedema Questionable value in cerebral oedema following trauma, cerebrovascular oedema Valuable in oedema associated with neoplasm and parasites 10. Malignancy Part of multi drug regimens for acute lymphatic leukaemia (children), chronic lymphatic leukaemia (adult)
42
Non-endocrine diseases
11. Liver diseases
Subacute hepatic necrosis & chronic active hepatitis: Improves survival rates Alcoholic hepatitis: reserved for pts. with severe illness Non-alcoholic cirrhosis: helpful if no ascites
12. Shock
Often helpful but no convincing evidence
Non-endocrine diseases
- Miscellaneous
Organ transplantation Bells palsy Thrombocytopenia Myasthenia gravis Spinal cord injury
44
Dosage schedule
Goal of therapy:
To relieve pain or distressing symptom (e.g.,
rheumatoid arthritis): start with low dose To treat life threatening condition (e.g., pemphigus): initial dose must be high
Body weight X-ray of spine Blood glucose Examination of the eye B.P.
46
Steroid withdrawal
Longer the duration of therapy, slower the withdrawal Less than 1 week: withdrawal in few steps
Rapid withdrawal: 50% reduction of dose every day Slow withdrawal: 2.5 5 mg prednisolone reduced at an interval of 2-3 days
Adverse effects
Two types :
From abrupt withdrawal Chronic therapeutic use of high doses.
1. Abrupt Withdrawal Flare up of underlying disease Suppression of HPA axis and acute adrenal insufficiency. Increase in ICT and papilledema.
48
Cushingoid habitus
High blood sugar High blood pressure Vertigo Blurred vision Female baldness Menstrual irregularities Hirsutism Severe depression Cognitive impairment Emotional instability Easy fatigability
49
Hypertension, diabetes, heart failure, osteoporosis, glaucoma, epilepsy, mood disorders, pressure sores.
Conditions where potassium loss will prove dangerous Situations where muscle weakening could be problematic
Liver failure
Interactions
1. Some drugs intensify the adverse reactions of corticosteroids:
Increased risk of gastro-intestinal bleeding: alcohol, anticoagulants, aspirin, NSAIDs Increased fluid retention and hypertension: beta2 agonists, NSAIDs, sodium-containing preparations, oestrogens, liquorice, ginseng, some Asian herbal mixtures Increased potassium depletion: beta2 agonists, diuretics, digoxin, laxatives
53
Interactions
2. The effects of some drugs and appliances are antagonised:
anti-epileptics, anti-diabetics, anti-hypertensives, growth hormone, intra-uterine contraceptive devices.
3.
4.
Misuses
Illogical use by unqualified practitioners/faith healers
Excessive Dose Prolonged Duration No clinical Indication
56
THANK YOU
57